Clinical Trial Update: PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating 16- or 24-week pegylated interferon alfa-2a plus ribavirin in adults with chronic hepatitis C genotype 2 who have a rapid virologic res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIFN alfa-2a (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Pusan National University Yangsan Hospital | Conditions: Chronic Hepatitis C | Phase 4 | Status: UNKNOWN